ROTH Capital downgraded Soliton from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
IRVINE, Calif., Dec. 16, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ:SOLY). The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite. The RESONIC™ device initially received U.S. Food and Drug Administration (FDA) 510(k) clearance for the short-term improvement in the appearance of cellulite, and that clearance has now been expanded to long-term improvement up to one year. In recent clinical data submitted to the FDA, RESONIC™ demonstrated sig
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Soliton, Inc. /Tx/ (NASDAQ:SOLY) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentation/78926To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile.About Investor NetworkInvestor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the profess
HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary aesthetic platform technology, today announced Brad Hauser, President & CEO of Soliton, has been named as an Aesthetic Industry Association (AIA) advisory board member. "I am excited to be joining the Aesthetic Industry Association advisory board as I believe this association provides substantial thought leadership to the aesthetic industry," commented Brad Hauser, President & CEO of Soliton. "As Soliton continues to elevate the market and drive towards commercialization, the learnings will create a real symbiotic relationship between Sol
15-12B - Soliton, Inc. (0001548187) (Filer)
EFFECT - Soliton, Inc. (0001548187) (Filer)
EFFECT - Soliton, Inc. (0001548187) (Filer)
4 - Soliton, Inc. (0001548187) (Issuer)
4 - Soliton, Inc. (0001548187) (Issuer)
4 - Soliton, Inc. (0001548187) (Issuer)
ROTH Capital downgraded Soliton from Buy to Neutral
Cantor Fitzgerald downgraded Soliton from Overweight to Neutral and set a new price target of $22.60 from $25.00 previously
Cantor Fitzgerald downgraded Soliton from Overweight to Neutral
SC 13D/A - Soliton, Inc. (0001548187) (Subject)